David F. Stroncek

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy

Terry J. Fry, Nirali N. Shah, Rimas J. Orentas et al. · Nature Medicine · 2017 · 1.3K citations · Full text

Allergy, Autoimmune Disease, Cd19-targeted Car Immunotherapy +9

T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma

Jennifer N. Brudno, Irina Marić, Steven D. Hartman et al. · Journal of Clinical Oncology · 2018 · 778 citations · Full text

T cells expressing an anti–B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma

Syed Abbas Ali, Victoria Shi, Irina Marić et al. · Blood · 2016 · 753 citations · Full text

NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis

Chi Ma, Aparna H. Kesarwala, Tobias Eggert et al. · Nature · 2016 · 741 citations · Full text

Liver Physiology, T-regulatory Cell, Immunology +8

International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials

Jacques Galipeau, Mauro Krampera, John Barrett et al. · Cytotherapy · 2015 · 491 citations · Full text

Cell Therapy, International Society, Medicine +10